Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med.

Enviado por remote_content el Lun, 21/10/2024 - 08:34

Enfermedades infecciosas

WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Alvarez-Moreno CA, Bravo J, Saavedra C, Chacon J, Zuluaga I, et al, 2/12/2020.

BACKGROUND
World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19).

CONCLUSIONS
These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.)

Read full article

Investigación y educación

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med.

Artículos que te pueden interesar

Impact of TR34/L98H, TR46/Y121F/T289A and TR53 Alterations in Azole-Resistant Aspergillus fumigatus on Sterol Composition and Modifications after In Vitro Exposure to Itraconazole and Voriconazole. Microorganisms.

Consensus recommendations based on evidence for abdominal sepsis in the pediatric and adult population of colombia. Infectio,

Guía de práctica clínica para la tamización de pacientes con riesgo de colonización por Enterobacterales productores de carbapenemasas y el manejo de infecciones causadas por estas bacterias]. Rev. Fac. Med.